文献速递湿疹皮炎与荨麻疹

度普利尤单抗在6至<12岁重度特应性皮炎儿童中的长期安全性和有效性

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
PubMed 文献 · Br J Dermatol · 2020-10-09

这项开放标签IIa期及后续III期开放标签扩展研究纳入38例6至<12岁重度特应性皮炎儿童,评估度普利尤单抗的药代动力学、长期安全性和有效性。结果显示治疗不良事件多为轻至中度且短暂,无因不良事件停药,EASI和PP-NRS在第52周分别改善-92%/-84%和-70%/-58%,支持其作为长期连续治疗。

要点

  • 度普利尤单抗在6至<12岁重度特应性皮炎儿童中显示有利的长期安全性和有效性。
  • 常见不良事件为鼻咽炎和特应性皮炎加重,多为轻至中度且短暂。
  • 第52周EASI和PP-NRS分别改善-92%/-84%和-70%/-58%。

核心结论

  • 度普利尤单抗可作为6至<12岁重度特应性皮炎儿童的长期连续治疗。

研究设计与样本

  • 全球多中心、IIa期开放标签、递增剂量、序贯队列研究及后续开放标签扩展研究。
  • 纳入38例6至<12岁重度特应性皮炎儿童,37例完成IIa期,33例继续进入扩展期。

主要发现

  • 度普利尤单抗浓度呈非线性靶点介导药代动力学,第24-48周平均血清浓度2 mg/kg组为61-77 mg/L,4 mg/kg组为143-181 mg/L。
  • 治疗出现的不良事件多为轻至中度且短暂,无导致停药者;最常见为鼻咽炎(2 mg/kg组47%,4 mg/kg组56%)和特应性皮炎加重(分别为29%和13%)。
  • 单次给药后特应性皮炎迅速改善,并持续至第52周;第2周EASI和PP-NRS分别改善-37%/-33%和-17%/-20%,第52周分别改善-92%/-84%和-70%/-58%。

临床怎么用

  • 对于6至<12岁重度特应性皮炎儿童,可考虑使用度普利尤单抗进行长期连续治疗。

局限性

  • 研究为开放标签设计,样本量较小(38例),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16-week, randomized, placebo-controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4/IL-13 signalling, significantly improved signs and symptoms with acceptable safety; longer-term safety and efficacy data are lacking. OBJECTIVES: To report the pharmacokinetic profile and long-term safety and efficacy of dupilumab in children (aged ≥ 6 to < 12 years) with severe AD. METHODS: Children (aged ≥ 6 to < 12 years) with severe AD were enrolled in a global, multicentre, phase IIa, open-label, ascending-dose, sequential cohort study and subsequent open-label extension (OLE) study. Patients received single-dose dupilumab 2 or 4 mg kg-1 followed by 8-week pharmacokinetic sampling, then 2 or 4 mg kg-1 weekly for 4 weeks (phase IIa), followed by the same weekly regimen (OLE). Primary endpoints were dupilumab concentration-time profile and treatment-emergent adverse events (TEAEs); secondary assessments included Eczema Area and Severity Index (EASI) and Peak Pruritus Numeric Rating Scale (PP-NRS) score. RESULTS: Of 38 children enrolled, 37 completed phase IIa and 33 continued to the OLE. Nonlinear, target-mediated pharmacokinetics characterized dupilumab concentrations (week 24-48 mean serum concentrations: 2 mg kg-1 , 61-77 mg L-1 ; 4 mg kg-1 , 143-181 mg L-1 ). TEAEs were mostly mild to moderate and transient; none led to treatment discontinuation. The most commonly reported TEAEs were nasopharyngitis (2 mg kg-1 , 47%; 4 mg kg-1 , 56%) and AD exacerbation (29% and 13%, respectively). Single-dose dupilumab rapidly improved AD with further improvements through week 52. Mean EASI and PP-NRS improved by -37%/-33% and -17%/-20% at week 2 (phase IIa) and -92%/-84% and -70%/-58% at week 52 (OLE), respectively. CONCLUSIONS: These safety and efficacy results support the use of dupilumab as a continuous long-term treatment for children aged ≥ 6 to < 12 years with severe AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2020. PMID: 32969489. doi:10.1111/bjd.19460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。